# OnCo record ltz-301 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ltz-301/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ltz-301" ;
  schema:name "LTZ-301"@en ;
  schema:description "LTZ-301 is an experimental bispecific antibody from LTZ Therapeutics, in phase 1 trials for relapsed or refractory B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma and other cancers."@en ;
  schema:url <https://onco.cc/drugs/ltz-301/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.ltztherapeutics.com/html/news/118.html>, <https://www.ltztherapeutics.com/pipeline/index.html>, <https://clinicaltrials.gov/search?intr=LTZ-301> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Bispecific antibody (myeloid cell engager)" ;
  onco:cancers <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/> ;
  onco:targets <https://onco.cc/targets/cd79b/> ;
  onco:companies <https://onco.cc/companies/ltz-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct07121946/> .